Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02700919 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by Mereo BioPharma.

Completed
Registry status
Phase 2
Development phase
282
Enrollment target
20
Study locations

NCT02700919 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Mereo BioPharma. The registered enrollment target is 282 participants, below the 1,040-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02700919, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Mereo BioPharma.

COMPLETED
Registry status
Phase 2
Development phase
282 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the efficacy and safety of BCT197 when added on to standard of care in adult subjects with acute respiratory exacerbations of chronic obstructive pulmonary disease requiring hospitalization. Additionally, the study will characterize the pharmacokinetics of BCT197 in adults with COPD. The total duration of the study will be 26 weeks. Subjects will receive study treatment administration over a period of 5 days after randomization. It is expected that approximately 255 subjects will complete the study and follow-up.

Conditions Studied

Pulmonary Disease, Chronic Obstructive

Interventions

  • DRUG Placebo
  • DRUG BCT197

Study Locations (20)

Other

  • Mereo Research Site - Dupnitsa
  • Mereo Research Site - Gabrovo
  • Mereo Research Site - Kardzhali
  • Mereo Research Site - Kozloduy
  • Mereo Research Site - Kyustendil
  • Mereo Research Site - Lovech
  • Mereo Research Site - Montana
  • Mereo Research Site - Razgrad
  • Mereo Research Site - Rousse
  • Mereo Research Site - Shumen
  • Mereo Research Site - Sliven
  • Mereo Research Site - Sofia
  • Mereo Research Site - Kyjov
  • Mereo Research Site - Mělník
  • Mereo Research Site - Slaný
  • Mereo Research Site - Dresden
  • Mereo Research Site - Balassagyarmat

Indiana

  • Mereo Research Site - Michigan City

Maryland

  • Mereo Research Site - Baltimore

Wisconsin

  • Mereo Research Site - Milwaukee

Trial Details

FieldValue
Enrollment Target 282 participants
Start Date 2016-08-01
Est. Completion 2017-11-28
Phase Phase 2

Sponsor

Mereo BioPharma

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02700919

The ClinicalTrials.gov registry entry for NCT02700919 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,040-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (73% lower). The listed sponsor is Mereo BioPharma, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02700919 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Indiana, Maryland.

Frequently Asked Questions

What is clinical trial NCT02700919 about?

NCT02700919 is a clinical study titled "Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease". The purpose of this study is to compare the efficacy and safety of BCT197 when added on to standard of care in adult subjects with acute respiratory exacerbations of chronic obstructive pulmonary disease requiring hospitalization. Additionally, the study will characterize the pharmacokinetics of BCT...

What is the current status of trial NCT02700919?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2016-08-01. Estimated completion is 2017-11-28.

What conditions does trial NCT02700919 study?

This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.

What interventions are being tested in trial NCT02700919?

The interventions under investigation include: Placebo (DRUG), BCT197 (DRUG).

Who is sponsoring clinical trial NCT02700919?

This trial is sponsored by Mereo BioPharma, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02700919 being conducted?

This trial has 20 study locations across Indiana, Maryland, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Disease, Chronic Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Disease, Chronic Obstructive

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.